The PREDICT (increasing the participation of the elderly in clinical trials) study: The charter and beyond

Peter Crome; Antonio Cherubini; Joaquim Oristrell

doi:10.1586/17512433.2014.922864

The PREDICT (increasing the participation of the elderly in clinical trials) study: The charter and beyond

Peter Crome, Antonio Cherubini, Joaquim Oristrell

Istituto Nazionale di Riposo e Cura per Anziani V.E. II

Research output: Contribution to journal › Article › peer-review

Abstract

There is general agreement that the growth of the numbers of older people throughout the world has significant implications for both health and social care and for the prevention and treatment of disease and disability. The optimum use of pharmaceuticals and possibly nutraceuticals is, and will to a greater extent, therefore be of crucial importance. A snapshot of the current status of older people in relation to the issues discussed in this review is provided in an informative report published by Age UK.

Original language	English
Pages (from-to)	457-468
Number of pages	12
Journal	Expert Review of Clinical Pharmacology
Volume	7
Issue number	4
DOIs	https://doi.org/10.1586/17512433.2014.922864
Publication status	Published - 2014

Keywords

cardiovascular disease
clinical trial
drug treatment
older people
patients view

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology, Toxicology and Pharmaceutics(all)
Medicine(all)

Access to Document

10.1586/17512433.2014.922864

Fingerprint Dive into the research topics of 'The PREDICT (increasing the participation of the elderly in clinical trials) study: The charter and beyond'. Together they form a unique fingerprint.

Cite this

@article{da1f8fd2485e45a3b84bfced5ac7e128,

title = "The PREDICT (increasing the participation of the elderly in clinical trials) study: The charter and beyond",

abstract = "There is general agreement that the growth of the numbers of older people throughout the world has significant implications for both health and social care and for the prevention and treatment of disease and disability. The optimum use of pharmaceuticals and possibly nutraceuticals is, and will to a greater extent, therefore be of crucial importance. A snapshot of the current status of older people in relation to the issues discussed in this review is provided in an informative report published by Age UK.",

keywords = "cardiovascular disease, clinical trial, drug treatment, older people, patients view",

author = "Peter Crome and Antonio Cherubini and Joaquim Oristrell",

year = "2014",

doi = "10.1586/17512433.2014.922864",

language = "English",

volume = "7",

pages = "457--468",

journal = "Expert Review of Clinical Pharmacology",

issn = "1751-2433",

publisher = "ROUTLEDGE JOURNALS, TAYLOR FRANCIS LTD",

number = "4",

}

TY - JOUR

T1 - The PREDICT (increasing the participation of the elderly in clinical trials) study

T2 - The charter and beyond

AU - Crome, Peter

AU - Cherubini, Antonio

AU - Oristrell, Joaquim

PY - 2014

Y1 - 2014

N2 - There is general agreement that the growth of the numbers of older people throughout the world has significant implications for both health and social care and for the prevention and treatment of disease and disability. The optimum use of pharmaceuticals and possibly nutraceuticals is, and will to a greater extent, therefore be of crucial importance. A snapshot of the current status of older people in relation to the issues discussed in this review is provided in an informative report published by Age UK.

AB - There is general agreement that the growth of the numbers of older people throughout the world has significant implications for both health and social care and for the prevention and treatment of disease and disability. The optimum use of pharmaceuticals and possibly nutraceuticals is, and will to a greater extent, therefore be of crucial importance. A snapshot of the current status of older people in relation to the issues discussed in this review is provided in an informative report published by Age UK.

KW - cardiovascular disease

KW - clinical trial

KW - drug treatment

KW - older people

KW - patients view

UR - http://www.scopus.com/inward/record.url?scp=84903153097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903153097&partnerID=8YFLogxK

U2 - 10.1586/17512433.2014.922864

DO - 10.1586/17512433.2014.922864

M3 - Article

C2 - 24939469

AN - SCOPUS:84903153097

VL - 7

SP - 457

EP - 468

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 4

ER -